Ruxolitinib’s inhibition of the JAK2-STAT pathway reduces eosinophil survival signals mediated by IL-5 and GM-CSF, potentially benefiting patients with refractory or advanced CEL. This evidence concerns the gene JAK2 and Chronic Eosinophilic Leukemia, Not Otherwise Specified.